

**Clinical trial results:****A Phase IIIB, Randomized, Open Label, Feasibility Study of a Single Priming Dose of Meningococcal Group C Conjugate Vaccine (NeisVac-C) in Infants****Summary**

EudraCT number	2010-019383-36
Trial protocol	PL ES
Global end of trial date	31 January 2012

**Results information**

Result version number	v1
This version publication date	29 June 2016
First version publication date	05 August 2015

**Trial information****Trial identification**

Sponsor protocol code	670901
-----------------------	--------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01218451
WHO universal trial number (UTN)	-
Other trial identifiers	Alias: B9361011

Notes:

**Sponsors**

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., 001 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., 001 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	27 July 2012
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	31 January 2012
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To assess the feasibility of a single priming dose of NeisVac-C in infants (at either 4 or 6 months of age), as determined by immune response.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	28 September 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 835
Country: Number of subjects enrolled	Spain: 111
Worldwide total number of subjects	946
EEA total number of subjects	946

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	946
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Study was conducted in Poland and Spain. Study was initiated on 28 Sep 2010 and completed on 31 Jan 2012.

### Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	NeisVac-C: Group 1

Arm description:

Subjects received single dose of NeisVac-C at 4 months of age along with Infanrix hexa and Prevenar 13 at 2, 4 and 6 months of age, and booster vaccination of all the vaccines between the age of 12 and 13 months.

Arm type	Experimental
Investigational medicinal product name	NeisVac-C
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

A single 0.5 millilitre (mL) dose at 4 months of age, with booster vaccinations between 12 and 13 months of age.

Investigational medicinal product name	Infanrix hexa
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

0.5 mL Infanrix hexa at 2, 4 and 6 months of age, with booster vaccinations between 12 and 13 months of age.

Investigational medicinal product name	Prevenar 13
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

0.5 mL Prevenar 13 at 2, 4 and 6 months of age, with booster vaccinations between 12 and 13 months of age.

<b>Arm title</b>	NeisVac-C: Group 2
------------------	--------------------

Arm description:

Subjects received single dose of NeisVac-C at 6 months of age along with Infanrix hexa and Prevenar 13 at 2, 4 and 6 months of age, and booster vaccination of all the vaccines between the age of 12 and 13 months.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	NeisVac-C
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

A single 0.5mL dose at 6 months of age with booster vaccination between 12 and 13 months of age.

Investigational medicinal product name	Infanrix hexa
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

0.5 mL Infanrix hexa at 2, 4 and 6 months of age, with booster vaccinations between 12 and 13 months of age.

Investigational medicinal product name	Prevenar 13
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

0.5 mL Prevenar 13 at 2, 4 and 6 months of age, with booster vaccinations between 12 and 13 months of age.

<b>Arm title</b>	NeisVac-C: Group 3
------------------	--------------------

Arm description:

Subjects received two doses of NeisVac-C one each at 2 and 4 months of age along with Infanrix hexa and Prevenar 13 at 2, 4 and 6 months of age, with booster vaccinations of all the vaccines between 12 and 13 months of age.

Arm type	Experimental
Investigational medicinal product name	NeisVac-C
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

A single 0.5mL dose at either 2 or 4 month of age with booster vaccination between 12 and 13 months of age.

Investigational medicinal product name	Infanrix hexa
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

0.5 mL Infanrix hexa at 2, 4 and 6 months of age, with booster vaccinations between 12 and 13 months of age.

Investigational medicinal product name	Prevenar 13
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

0.5 mL Prevenar 13 at 2, 4 and 6 months of age, with booster vaccinations between 12 and 13 months of age.

<b>Number of subjects in period 1</b> <sup>[1]</sup>	NeisVac-C: Group 1	NeisVac-C: Group 2	NeisVac-C: Group 3
Started	318	312	315
Completed	307	300	297
Not completed	11	12	18
Consent withdrawn by subject	1	4	9
Adverse event	3	1	2
Unspecified	7	2	3
Lost to follow-up	-	5	4

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: One subject was excluded from the safety analysis dataset because NeisVac-C vaccinations were administered at Months 2, 4 and 6.

## Baseline characteristics

### Reporting groups

Reporting group title	NeisVac-C: Group 1
Reporting group description:	
Subjects received single dose of NeisVac-C at 4 months of age along with Infanrix hexa and Prevenar 13 at 2, 4 and 6 months of age, and booster vaccination of all the vaccines between the age of 12 and 13 months.	
Reporting group title	NeisVac-C: Group 2
Reporting group description:	
Subjects received single dose of NeisVac-C at 6 months of age along with Infanrix hexa and Prevenar 13 at 2, 4 and 6 months of age, and booster vaccination of all the vaccines between the age of 12 and 13 months.	
Reporting group title	NeisVac-C: Group 3
Reporting group description:	
Subjects received two doses of NeisVac-C one each at 2 and 4 months of age along with Infanrix hexa and Prevenar 13 at 2, 4 and 6 months of age, with booster vaccinations of all the vaccines between 12 and 13 months of age.	

Reporting group values	NeisVac-C: Group 1	NeisVac-C: Group 2	NeisVac-C: Group 3
Number of subjects	318	312	315
Age categorical Units: Subjects			

Age continuous Units: weeks			
arithmetic mean	7.7	7.6	7.7
standard deviation	± 1.49	± 1.45	± 1.45
Gender categorical Units: Subjects			
Female	145	145	158
Male	173	167	157

Reporting group values	Total		
Number of subjects	945		
Age categorical Units: Subjects			

Age continuous Units: weeks			
arithmetic mean	-		
standard deviation			
Gender categorical Units: Subjects			
Female	448		
Male	497		

## End points

### End points reporting groups

Reporting group title	NeisVac-C: Group 1
Reporting group description: Subjects received single dose of NeisVac-C at 4 months of age along with Infanrix hexa and Prevenar 13 at 2, 4 and 6 months of age, and booster vaccination of all the vaccines between the age of 12 and 13 months.	
Reporting group title	NeisVac-C: Group 2
Reporting group description: Subjects received single dose of NeisVac-C at 6 months of age along with Infanrix hexa and Prevenar 13 at 2, 4 and 6 months of age, and booster vaccination of all the vaccines between the age of 12 and 13 months.	
Reporting group title	NeisVac-C: Group 3
Reporting group description: Subjects received two doses of NeisVac-C one each at 2 and 4 months of age along with Infanrix hexa and Prevenar 13 at 2, 4 and 6 months of age, with booster vaccinations of all the vaccines between 12 and 13 months of age.	

### Primary: Proportion of Subjects With Seroprotective Antibody Titers 1 Month After Completion of the Primary Vaccination

End point title	Proportion of Subjects With Seroprotective Antibody Titers 1 Month After Completion of the Primary Vaccination
End point description: Number of subjects achieving seroprotective antibody titre (Serum bactericidal activity [rSBA] greater than or equal to [ $\geq$ ] 8), 1 month after the primary vaccination of NeisVac-C was reported. Per protocol analysis data set contained all randomized and vaccinated subjects who fulfilled the exclusion/inclusion criteria, had no major protocol deviation affecting the estimate of treatment effect and had immunogenicity measurements available for at least one of the three co-primary endpoints.	
End point type	Primary
End point timeframe: 1 month after primary vaccination	

End point values	NeisVac-C: Group 1	NeisVac-C: Group 2	NeisVac-C: Group 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	271	265	250	
Units: Proportion of subjects				
number (confidence interval 90%)	99.6 (98.3 to 100)	99.2 (97.6 to 99.9)	99.6 (98.1 to 100)	

### Statistical analyses

Statistical analysis title	Response Rate (Group 2 vs Group 3)
Statistical analysis description: Non-inferiority margin was set to -10%. 90% Confidence Interval (CI) for the difference in the proportion of subjects with rSBA $\geq$ 8 was calculated between Group 2 and Group 3.	
Comparison groups	NeisVac-C: Group 3 v NeisVac-C: Group 2

Number of subjects included in analysis	515
Analysis specification	Pre-specified
Analysis type	non-inferiority
Parameter estimate	Difference in proportion
Point estimate	-0.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.9
upper limit	1.1

<b>Statistical analysis title</b>	Response Rate (Group 1 vs Group 3)
-----------------------------------	------------------------------------

Statistical analysis description:

Non-inferiority margin was set to -10%. 90% CI for the difference in the proportion of subjects with rSBA  $\geq$  8 was calculated between Group 1 and Group 3.

Comparison groups	NeisVac-C: Group 1 v NeisVac-C: Group 3
Number of subjects included in analysis	521
Analysis specification	Pre-specified
Analysis type	non-inferiority
Parameter estimate	Difference in proportion
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.3
upper limit	1.4

### **Primary: Proportion of Subjects With Seroprotective Antibody Titers Prior to the Administration of the Booster Dose**

End point title	Proportion of Subjects With Seroprotective Antibody Titers Prior to the Administration of the Booster Dose
-----------------	--

End point description:

Number of subjects achieving seroprotective antibody titre (rSBA  $\geq$  8) prior to the administration of the booster vaccination of NeisVac-C was reported. Per protocol analysis data set contained all randomized and vaccinated subjects who fulfilled the exclusion/inclusion criteria, had no major protocol deviation affecting the estimate of treatment effect and had immunogenicity measurements available for at least one of the three co-primary endpoints.

End point type	Primary
----------------	---------

End point timeframe:

Before Booster Dose

<b>End point values</b>	NeisVac-C: Group 1	NeisVac-C: Group 2	NeisVac-C: Group 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	264 <sup>[1]</sup>	258 <sup>[2]</sup>	245 <sup>[3]</sup>	
Units: Proportion of subjects				
number (confidence interval 90%)	78 (73.4 to 82.2)	90.7 (87.2 to 93.5)	67.8 (62.5 to 72.7)	

Notes:

[1] - Number of subjects evaluable for this endpoint.

[2] - Number of subjects evaluable for this endpoint.

[3] - Number of subjects evaluable for this endpoint.

## Statistical analyses

<b>Statistical analysis title</b>	Response Rate (Group 2 vs Group 3)
Statistical analysis description: Non-inferiority margin was set to -10%. 90% CI for the difference in the proportion of subjects with rSBA >= 8 was calculated between Group 2 and Group 3.	
Comparison groups	NeisVac-C: Group 2 v NeisVac-C: Group 3
Number of subjects included in analysis	503
Analysis specification	Pre-specified
Analysis type	non-inferiority
Parameter estimate	Difference in proportion
Point estimate	22.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	17.2
upper limit	28.7

<b>Statistical analysis title</b>	Response Rate (Group 1 vs Group 3)
Statistical analysis description: Non-inferiority margin was set to -10%. 90% CI for the difference in the proportion of subjects with rSBA >= 8 was calculated between Group 1 and Group 3.	
Comparison groups	NeisVac-C: Group 1 v NeisVac-C: Group 3
Number of subjects included in analysis	509
Analysis specification	Pre-specified
Analysis type	non-inferiority
Parameter estimate	Difference in proportion
Point estimate	10.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	3.8
upper limit	16.7

## Primary: Proportion of Subjects With Seroprotective Antibody Titers 1 Month After the Administration of the Booster Dose.

End point title	Proportion of Subjects With Seroprotective Antibody Titers 1 Month After the Administration of the Booster Dose.
End point description:	Number of subjects achieving seroprotective antibody titre (rSBA $\geq$ 128), 1 month after the administration of booster vaccination of NeisVac-C was reported. The per protocol analysis data set contained all randomized and vaccinated subjects who fulfilled the exclusion/inclusion criteria, had no major protocol deviation affecting the estimate of treatment effect and had immunogenicity measurements available for at least one of the three co-primary endpoints.
End point type	Primary
End point timeframe:	1 month after booster dose

End point values	NeisVac-C: Group 1	NeisVac-C: Group 2	NeisVac-C: Group 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	264 <sup>[4]</sup>	258 <sup>[5]</sup>	243 <sup>[6]</sup>	
Units: Proportion of subjects				
number (confidence interval 90%)	98.9 (97.1 to 99.7)	99.6 (98.2 to 100)	99.6 (98.1 to 100)	

Notes:

[4] - Number of subjects evaluable for this endpoint.

[5] - Number of subjects evaluable for this endpoint.

[6] - Number of subjects evaluable for this endpoint.

### Statistical analyses

<b>Statistical analysis title</b>	Response Rate (Group 2 vs Group 3)
Statistical analysis description:	Non-inferiority margin was set to -5%. 90% CI for the difference in the proportion of subjects with rSBA $\geq$ 128 was calculated between Group 2 and Group 3.
Comparison groups	NeisVac-C: Group 2 v NeisVac-C: Group 3
Number of subjects included in analysis	501
Analysis specification	Pre-specified
Analysis type	non-inferiority
Parameter estimate	Difference in proportion
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.3
upper limit	1.5

<b>Statistical analysis title</b>	Response Rate (Group 1 vs Group 3)
Statistical analysis description:	Non-inferiority margin was set to -5%. 90% CI for the difference in the proportion of subjects with rSBA $\geq$ 128 was calculated between Group 1 and Group 3.
Comparison groups	NeisVac-C: Group 1 v NeisVac-C: Group 3

Number of subjects included in analysis	507
Analysis specification	Pre-specified
Analysis type	non-inferiority
Parameter estimate	Difference in proportion
Point estimate	-0.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.5
upper limit	0.8

### Secondary: Geometric Mean Titer for Serum Bactericidal Activity (rSBA) 1 Month After Completion of the Primary Vaccination

End point title	Geometric Mean Titer for Serum Bactericidal Activity (rSBA) 1 Month After Completion of the Primary Vaccination
-----------------	---

End point description:

rSBA titer 1 month after primary vaccination with NeisVac-C was reported. The immunogenicity analysis data set contained all randomized and vaccinated subjects (at least one vaccination with NeisVac-C) with available data for the immunogenicity analysis, i.e. with both baseline and at least one post-baseline immunogenicity measurement available.

End point type	Secondary
----------------	-----------

End point timeframe:

1 month after primary vaccination

End point values	NeisVac-C: Group 1	NeisVac-C: Group 2	NeisVac-C: Group 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	315 <sup>[7]</sup>	306 <sup>[8]</sup>	301 <sup>[9]</sup>	
Units: Titer				
geometric mean (confidence interval 95%)	372.1 (339.4 to 408.1)	401.8 (361.6 to 446.5)	624.1 (568.2 to 685.5)	

Notes:

[7] - Number of subjects evaluable for this endpoint.

[8] - Number of subjects evaluable for this endpoint.

[9] - Number of subjects evaluable for this endpoint.

### Statistical analyses

No statistical analyses for this end point

### Secondary: Geometric Mean titer for Serum bactericidal Activity (rSBA) Prior to the Administration of the Booster Dose

End point title	Geometric Mean titer for Serum bactericidal Activity (rSBA) Prior to the Administration of the Booster Dose
-----------------	---

End point description:

rSBA titers prior to the administration of booster dose of NeisVac-C was reported. The immunogenicity analysis data set contained all randomized and vaccinated subjects (at least one vaccination with NeisVac-C) with available data for the immunogenicity analysis, i.e. with both baseline and at least one post-baseline immunogenicity measurement available.

End point type	Secondary
----------------	-----------

End point timeframe:

Before Booster dose

<b>End point values</b>	NeisVac-C: Group 1	NeisVac-C: Group 2	NeisVac-C: Group 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	297 <sup>[10]</sup>	293 <sup>[11]</sup>	285 <sup>[12]</sup>	
Units: Titer				
geometric mean (confidence interval 95%)	38.5 (32.3 to 45.9)	84.8 (71.9 to 100.1)	29.5 (24.4 to 35.7)	

Notes:

[10] - Number of subjects evaluable for this endpoint.

[11] - Number of subjects evaluable for this endpoint.

[12] - Number of subjects evaluable for this endpoint.

### Statistical analyses

No statistical analyses for this end point

### Secondary: Geometric Mean Titer for Serum Bactericidal Activity (rSBA) 1 Month After the Administration of the Booster Dose.

End point title	Geometric Mean Titer for Serum Bactericidal Activity (rSBA) 1 Month After the Administration of the Booster Dose.
-----------------	---

End point description:

rSBA titers after the administration of booster dose of NeisVac-C was reported. The immunogenicity analysis data set contained all randomized and vaccinated subjects (at least one vaccination with NeisVac-C) with available data for the immunogenicity analysis, i.e. with both baseline and at least one post-baseline immunogenicity measurement available.

End point type	Secondary
----------------	-----------

End point timeframe:

1 month after booster dose

<b>End point values</b>	NeisVac-C: Group 1	NeisVac-C: Group 2	NeisVac-C: Group 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	302 <sup>[13]</sup>	298 <sup>[14]</sup>	288 <sup>[15]</sup>	
Units: Titer				
geometric mean (confidence interval 95%)	2472.1 (2226.3 to 2745)	1874.8 (1684.4 to 2086.6)	1538 (1381.1 to 1712.6)	

Notes:

[13] - Number of subjects evaluable for this endpoint.

[14] - Number of subjects evaluable for this endpoint.

[15] - Number of subjects evaluable for this endpoint.

### Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects With Prespecified Injection Site Reactions by Severity

End point title	Number of Subjects With Prespecified Injection Site Reactions by Severity
-----------------	---

End point description:

Injection site reactions includes injection site pain, tenderness, redness, swelling, and induration. The severity of injection site reactions was rated for Redness, induration or swelling (diameter) as Mild (1.0–2.5 cm), Moderate (2.5.–5.0 cm) Severe (> 5.0 cm) and for Injection site pain or tenderness as Mild (No impairment of arm movement), Moderate (Impairment of arm movement) and Severe (Severe impairment, arm not moving). The safety analysis set contained all subjects vaccinated at least once with NeisVac-C.

End point type	Secondary
----------------	-----------

End point timeframe:

Within 3 days after primary, booster vaccination

End point values	NeisVac-C: Group 1	NeisVac-C: Group 2	NeisVac-C: Group 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	318	312	315	
Units: Subjects				
number (not applicable)				
After primary vaccination (Mild)	97	92	128	
After primary vaccination (Moderate)	35	39	50	
After primary vaccination (Severe)	3	7	5	
After primary vaccination (Unknown)	25	20	24	
After booster vaccination (Mild)	92	74	81	
After booster vaccination (Moderate)	44	58	47	
After booster vaccination (Severe)	2	13	12	
After booster vaccination (Unknown)	14	14	20	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects With Prespecified Systemic Reactions by Severity

End point title	Number of Subjects With Prespecified Systemic Reactions by Severity
-----------------	---

End point description:

Systemic reactions are treatment-related systemic adverse events. Systemic reactions were reported in subject diary and includes vomiting, sweating, inconsolable or persisting crying, irritability, sleepiness, and food rejection. The safety analysis set contained all subjects vaccinated at least once with NeisVac-C.

End point type	Secondary
----------------	-----------

End point timeframe:

Within 3 days after primary, booster vaccination

<b>End point values</b>	NeisVac-C: Group 1	NeisVac-C: Group 2	NeisVac-C: Group 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	318	312	315	
Units: Subjects				
number (not applicable)				
After primary vaccination (Mild)	173	157	193	
After primary vaccination (Moderate)	28	16	52	
After primary vaccination (Severe)	0	0	2	
After primary vaccination (Unknown)	0	0	0	
After booster vaccination (Mild)	129	135	120	
After booster vaccination (Moderate)	23	30	25	
After booster vaccination (Severe)	1	0	0	
After booster vaccination (Unknown)	0	0	0	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Adverse Events

End point title	Number of Subjects With Adverse Events
End point description:	
An Adverse Event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A Serious AE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. All the adverse events excluding serious adverse events were also reported. The safety analysis set contained all subjects vaccinated at least once with NeisVac-C.	
End point type	Secondary
End point timeframe:	
Screening to 1 month after booster vaccination	

<b>End point values</b>	NeisVac-C: Group 1	NeisVac-C: Group 2	NeisVac-C: Group 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	318	312	315	
Units: Number of subjects				
number (not applicable)				
Serious AEs	50	38	34	
Any Non-Serious Systemic AEs	312	304	305	

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Screening to 1 month after booster vaccination

Adverse event reporting additional description:

SAEs and AEs were grouped by system organ class and summarized. AEs included AEs collected in subject diary (local, systemic reactions) and AEs collected on case report form at each visit. MedDRA version was not captured, here 0.0 is included as dictionary version.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	0.0
--------------------	-----

### Reporting groups

Reporting group title	NeisVac-C: Group 1
-----------------------	--------------------

Reporting group description:

Subjects received single dose of NeisVac-C at 4 months of age along with Infanrix hexa and Prevenar 13 at 2, 4 and 6 months of age, and booster vaccination of all the vaccines between the age of 12 and 13 months.

Reporting group title	NeisVac-C: Group 2
-----------------------	--------------------

Reporting group description:

Subjects received single dose of NeisVac-C at 6 months of age along with Infanrix hexa and Prevenar 13 at 2, 4 and 6 months of age, and booster vaccination of all the vaccines between the age of 12 and 13 months.

Reporting group title	NeisVac-C: Group 3
-----------------------	--------------------

Reporting group description:

Subjects received two doses of NeisVac-C one each at 2 and 4 months of age along with Infanrix hexa and Prevenar 13 at 2, 4 and 6 months of age, with booster vaccinations of all the vaccines between 12 and 13 months of age.

<b>Serious adverse events</b>	NeisVac-C: Group 1	NeisVac-C: Group 2	NeisVac-C: Group 3
Total subjects affected by serious adverse events			
subjects affected / exposed	50 / 318 (15.72%)	38 / 312 (12.18%)	34 / 315 (10.79%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Nephroblastoma			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Phlebitis			

subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>General disorders and administration site conditions</b>			
Pyrexia			
subjects affected / exposed	2 / 318 (0.63%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Immune system disorders</b>			
Hypersensitivity			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Reproductive system and breast disorders</b>			
Balinitis			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Injury, poisoning and procedural complications</b>			
Fall			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head injury			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Congenital, familial and genetic disorders</b>			
Gene mutation			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Nervous system disorders</b>			

Convulsion			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurological symptom			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Iron deficiency anaemia			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Conjunctivitis			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			

subjects affected / exposed	2 / 318 (0.63%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gingivitis</b>			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Intussusception</b>			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Stomatitis</b>			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Vomiting</b>			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hepatobiliary disorders</b>			
<b>Hepatitis</b>			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Skin and subcutaneous tissue disorders</b>			
<b>Dermatitis atopic</b>			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Erythema multiforme</b>			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Urticaria</b>			

subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
<b>Anal abscess</b>			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Bacterial infection</b>			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Bronchiolitis</b>			
subjects affected / exposed	4 / 318 (1.26%)	3 / 312 (0.96%)	1 / 315 (0.32%)
occurrences causally related to treatment / all	0 / 5	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Bronchitis</b>			
subjects affected / exposed	8 / 318 (2.52%)	3 / 312 (0.96%)	3 / 315 (0.95%)
occurrences causally related to treatment / all	0 / 8	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Bronchopneumonia</b>			
subjects affected / exposed	1 / 318 (0.31%)	1 / 312 (0.32%)	4 / 315 (1.27%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Conjunctivitis infective</b>			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cytomegalovirus infection</b>			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Dermatitis infected</b>			

subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Exanthema subitum</b>			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	2 / 315 (0.63%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastroenteritis</b>			
subjects affected / exposed	6 / 318 (1.89%)	8 / 312 (2.56%)	5 / 315 (1.59%)
occurrences causally related to treatment / all	0 / 6	0 / 9	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastroenteritis rotavirus</b>			
subjects affected / exposed	5 / 318 (1.57%)	2 / 312 (0.64%)	1 / 315 (0.32%)
occurrences causally related to treatment / all	0 / 5	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastrointestinal infection</b>			
subjects affected / exposed	1 / 318 (0.31%)	2 / 312 (0.64%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Influenza</b>			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Laryngitis</b>			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Meningococcal sepsis</b>			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Otitis media</b>			

subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pharyngitis</b>			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pneumonia</b>			
subjects affected / exposed	8 / 318 (2.52%)	8 / 312 (2.56%)	3 / 315 (0.95%)
occurrences causally related to treatment / all	0 / 8	0 / 8	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pneumonia respiratory syncytial viral</b>			
subjects affected / exposed	2 / 318 (0.63%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pyelonephritis</b>			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pyelonephritis acute</b>			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Respiratory syncytial virus bronchiolitis</b>			
subjects affected / exposed	2 / 318 (0.63%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Respiratory tract infection</b>			
subjects affected / exposed	1 / 318 (0.31%)	3 / 312 (0.96%)	2 / 315 (0.63%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Rotavirus infection</b>			

subjects affected / exposed	2 / 318 (0.63%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	4 / 318 (1.26%)	4 / 312 (1.28%)	2 / 315 (0.63%)
occurrences causally related to treatment / all	0 / 4	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicella			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	1 / 315 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	NeisVac-C: Group 1	NeisVac-C: Group 2	NeisVac-C: Group 3
Total subjects affected by non-serious adverse events			
subjects affected / exposed	312 / 318 (98.11%)	304 / 312 (97.44%)	305 / 315 (96.83%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Haemangioma			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences (all)	0	0	1
Haemangioma of skin			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences (all)	1	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	0	1	0
Discomfort			

subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences (all)	0	0	2
Fatigue			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	0	1	0
Injection site haematoma (Systemic)			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	0	1	0
Injection site induration (Systemic)			
subjects affected / exposed	1 / 318 (0.31%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	1	1	0
Injection site pain (Systemic)			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	0	2	0
Injection site swelling (Systemic)			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences (all)	0	0	1
Irritability			
subjects affected / exposed	165 / 318 (51.89%)	187 / 312 (59.94%)	169 / 315 (53.65%)
occurrences (all)	320	373	328
Nodule			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences (all)	0	0	1
Pyrexia			
subjects affected / exposed	207 / 318 (65.09%)	206 / 312 (66.03%)	179 / 315 (56.83%)
occurrences (all)	385	413	350
Tenderness			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	0	2	0
Thirst			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences (all)	1	0	0
Vaccination site reaction			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences (all)	1	0	0
Vessel puncture site haematoma			

subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences (all)	1	0	0
Xerosis			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	0	1	0
Injection site erythema			
subjects affected / exposed	179 / 318 (56.29%)	196 / 312 (62.82%)	195 / 315 (61.90%)
occurrences (all)	501	610	522
Injection site haematoma			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences (all)	0	0	1
Injection site induration			
subjects affected / exposed	181 / 318 (56.92%)	204 / 312 (65.38%)	196 / 315 (62.22%)
occurrences (all)	567	692	522
Injection site inflammation			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences (all)	0	0	1
Injection site oedema			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	0	2	0
Injection site pain			
subjects affected / exposed	144 / 318 (45.28%)	156 / 312 (50.00%)	153 / 315 (48.57%)
occurrences (all)	681	736	712
Injection site papule			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	0	1	0
Injection site reaction			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	0	1	0
Injection site swelling			
subjects affected / exposed	130 / 318 (40.88%)	146 / 312 (46.79%)	136 / 315 (43.17%)
occurrences (all)	329	421	354
Injection site vesicles			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	0	2	0
Injection site warmth			

subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Puncture site reaction subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
Injection site rash subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
Immune system disorders			
Drug hypersensitivity subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	0 / 312 (0.00%) 0	3 / 315 (0.95%) 3
Food allergy subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	3 / 312 (0.96%) 3	2 / 315 (0.63%) 2
Milk allergy subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 1	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
Seasonal allergy subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Reproductive system and breast disorders			
Genital labial adhesions subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Posthitis subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	1 / 312 (0.32%) 1	1 / 315 (0.32%) 2
Respiratory, thoracic and mediastinal disorders			
Allergic cough subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 1	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
Allergic respiratory symptom subjects affected / exposed occurrences (all)	2 / 318 (0.63%) 2	0 / 312 (0.00%) 0	0 / 315 (0.00%) 0
Asthma			

subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences (all)	0	0	1
Bronchial hyperreactivity			
subjects affected / exposed	0 / 318 (0.00%)	2 / 312 (0.64%)	1 / 315 (0.32%)
occurrences (all)	0	2	1
Bronchitis chronic			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	0	1	0
Bronchospasm			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences (all)	0	0	5
Cough			
subjects affected / exposed	5 / 318 (1.57%)	20 / 312 (6.41%)	14 / 315 (4.44%)
occurrences (all)	6	23	17
Dysphonia			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	0	1	0
Dyspnoea			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences (all)	0	0	1
Interstitial lung disease			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences (all)	1	0	0
Nasal congestion			
subjects affected / exposed	0 / 318 (0.00%)	2 / 312 (0.64%)	1 / 315 (0.32%)
occurrences (all)	0	2	1
Oropharyngeal pain			
subjects affected / exposed	0 / 318 (0.00%)	2 / 312 (0.64%)	1 / 315 (0.32%)
occurrences (all)	0	2	1
Pulmonary artery stenosis			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences (all)	1	0	0
Rhinitis allergic			
subjects affected / exposed	2 / 318 (0.63%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences (all)	2	0	0
Rhinitis seasonal			

subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 1	0 / 312 (0.00%) 0	0 / 315 (0.00%) 0
Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	0 / 312 (0.00%) 0	1 / 315 (0.32%) 2
Wheezing subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 1	0 / 312 (0.00%) 0	0 / 315 (0.00%) 0
Psychiatric disorders			
Anxiety subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 1	0 / 312 (0.00%) 0	0 / 315 (0.00%) 0
Apathy subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Decreased activity subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 1	0 / 312 (0.00%) 0	0 / 315 (0.00%) 0
Food aversion subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
Psychomotor retardation subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
Restlessness subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Sleep disorder subjects affected / exposed occurrences (all)	101 / 318 (31.76%) 152	119 / 312 (38.14%) 180	110 / 315 (34.92%) 171
Investigations			
Body temperature increased subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	1 / 312 (0.32%) 1	1 / 315 (0.32%) 1
Cardiac murmur			

subjects affected / exposed occurrences (all)	3 / 318 (0.94%) 3	2 / 312 (0.64%) 2	2 / 315 (0.63%) 2
Cardiac murmur functional subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 1	0 / 312 (0.00%) 0	0 / 315 (0.00%) 0
Weight decreased subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
<b>Injury, poisoning and procedural complications</b>			
Animal scratch subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Arthropod bite subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
Burns second degree subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
Clavicle fracture subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Eye injury subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Head injury subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 1	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Joint dislocation subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
Limb injury subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	0 / 312 (0.00%) 0	2 / 315 (0.63%) 2
Multiple injuries			

subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
Nail injury subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
Procedural pain subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Road traffic accident subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
Thermal burn subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 1	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
<b>Congenital, familial and genetic disorders</b>			
Atrioventricular septal defect subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Craniotabes subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Dacryostenosis congenital subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 1	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Hip dysplasia subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	1 / 312 (0.32%) 1	1 / 315 (0.32%) 1
Hydrocele subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	0 / 312 (0.00%) 0	2 / 315 (0.63%) 2
Phimosis subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Plagiocephaly			

subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 1	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
<b>Nervous system disorders</b>			
Coordination abnormal subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Crying subjects affected / exposed occurrences (all)	139 / 318 (43.71%) 230	156 / 312 (50.00%) 239	139 / 315 (44.13%) 234
Hydrocephalus subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
Hypertonia subjects affected / exposed occurrences (all)	4 / 318 (1.26%) 4	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Hypotonia subjects affected / exposed occurrences (all)	2 / 318 (0.63%) 2	1 / 312 (0.32%) 1	1 / 315 (0.32%) 1
Somnolence subjects affected / exposed occurrences (all)	116 / 318 (36.48%) 179	144 / 312 (46.15%) 233	124 / 315 (39.37%) 187
<b>Blood and lymphatic system disorders</b>			
Anaemia subjects affected / exposed occurrences (all)	4 / 318 (1.26%) 4	9 / 312 (2.88%) 9	11 / 315 (3.49%) 15
Iron deficiency anaemia subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
Lymphadenitis subjects affected / exposed occurrences (all)	2 / 318 (0.63%) 2	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
Lymphadenopathy subjects affected / exposed occurrences (all)	10 / 318 (3.14%) 10	4 / 312 (1.28%) 4	6 / 315 (1.90%) 6
<b>Ear and labyrinth disorders</b>			

Ear pain			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences (all)	0	0	2
Tympanic membrane hyperaemia			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences (all)	1	0	0
Eye disorders			
Conjunctival irritation			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	0	1	0
Conjunctivitis			
subjects affected / exposed	28 / 318 (8.81%)	15 / 312 (4.81%)	16 / 315 (5.08%)
occurrences (all)	31	17	18
Dacryostenosis acquired			
subjects affected / exposed	1 / 318 (0.31%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	1	1	0
Erythema of eyelid			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	0	1	0
Eye discharge			
subjects affected / exposed	0 / 318 (0.00%)	3 / 312 (0.96%)	0 / 315 (0.00%)
occurrences (all)	0	4	0
Eye inflammation			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	0	1	0
Lacrimation increased			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences (all)	0	0	1
Strabismus			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	2 / 315 (0.63%)
occurrences (all)	0	0	2
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	0	1	0
Abdominal pain			

subjects affected / exposed	11 / 318 (3.46%)	12 / 312 (3.85%)	7 / 315 (2.22%)
occurrences (all)	13	13	8
Abdominal pain upper			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences (all)	1	0	0
Abnormal faeces			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences (all)	1	0	0
Aphthous stomatitis			
subjects affected / exposed	6 / 318 (1.89%)	3 / 312 (0.96%)	1 / 315 (0.32%)
occurrences (all)	6	3	1
Constipation			
subjects affected / exposed	6 / 318 (1.89%)	6 / 312 (1.92%)	7 / 315 (2.22%)
occurrences (all)	6	6	7
Diarrhoea			
subjects affected / exposed	27 / 318 (8.49%)	42 / 312 (13.46%)	29 / 315 (9.21%)
occurrences (all)	34	50	34
Dyspepsia			
subjects affected / exposed	0 / 318 (0.00%)	3 / 312 (0.96%)	2 / 315 (0.63%)
occurrences (all)	0	3	2
Enterocolitis			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	0	1	0
Faeces discoloured			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences (all)	1	0	0
Flatulence			
subjects affected / exposed	1 / 318 (0.31%)	1 / 312 (0.32%)	3 / 315 (0.95%)
occurrences (all)	1	1	4
Gastritis			
subjects affected / exposed	0 / 318 (0.00%)	2 / 312 (0.64%)	0 / 315 (0.00%)
occurrences (all)	0	2	0
Gastrooesophageal reflux disease			
subjects affected / exposed	2 / 318 (0.63%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences (all)	2	0	1
Gingival pain			

subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	1 / 315 (0.32%)
occurrences (all)	0	1	1
Gingivitis			
subjects affected / exposed	1 / 318 (0.31%)	1 / 312 (0.32%)	1 / 315 (0.32%)
occurrences (all)	1	1	1
Infantile colic			
subjects affected / exposed	1 / 318 (0.31%)	1 / 312 (0.32%)	2 / 315 (0.63%)
occurrences (all)	1	1	2
Inguinal hernia			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	1 / 315 (0.32%)
occurrences (all)	0	1	1
Mouth cyst			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	0	1	0
Mucous stools			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences (all)	1	0	0
Oral pain			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences (all)	0	0	1
Regurgitation			
subjects affected / exposed	3 / 318 (0.94%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences (all)	3	0	0
Stomatitis			
subjects affected / exposed	3 / 318 (0.94%)	2 / 312 (0.64%)	3 / 315 (0.95%)
occurrences (all)	4	2	4
Teething			
subjects affected / exposed	22 / 318 (6.92%)	25 / 312 (8.01%)	19 / 315 (6.03%)
occurrences (all)	35	47	31
Vomiting			
subjects affected / exposed	29 / 318 (9.12%)	25 / 312 (8.01%)	15 / 315 (4.76%)
occurrences (all)	34	31	15
Skin and subcutaneous tissue disorders			
Cafe au lait spots			
subjects affected / exposed	1 / 318 (0.31%)	1 / 312 (0.32%)	1 / 315 (0.32%)
occurrences (all)	1	1	1

Dermal cyst			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences (all)	0	0	1
Dermatitis			
subjects affected / exposed	3 / 318 (0.94%)	2 / 312 (0.64%)	6 / 315 (1.90%)
occurrences (all)	3	2	6
Dermatitis allergic			
subjects affected / exposed	15 / 318 (4.72%)	9 / 312 (2.88%)	13 / 315 (4.13%)
occurrences (all)	17	11	16
Dermatitis atopic			
subjects affected / exposed	31 / 318 (9.75%)	22 / 312 (7.05%)	21 / 315 (6.67%)
occurrences (all)	43	23	21
Dermatitis diaper			
subjects affected / exposed	6 / 318 (1.89%)	6 / 312 (1.92%)	5 / 315 (1.59%)
occurrences (all)	6	8	5
Dry skin			
subjects affected / exposed	1 / 318 (0.31%)	1 / 312 (0.32%)	1 / 315 (0.32%)
occurrences (all)	1	1	1
Eczema			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences (all)	1	0	0
Erythema			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	0	1	0
Heat rash			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	0	1	0
Hyperhidrosis			
subjects affected / exposed	28 / 318 (8.81%)	41 / 312 (13.14%)	40 / 315 (12.70%)
occurrences (all)	36	52	58
Papule			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences (all)	0	0	1
Rash			
subjects affected / exposed	8 / 318 (2.52%)	7 / 312 (2.24%)	9 / 315 (2.86%)
occurrences (all)	8	9	9

Rash macular subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 1	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Rash papular subjects affected / exposed occurrences (all)	2 / 318 (0.63%) 2	2 / 312 (0.64%) 2	0 / 315 (0.00%) 0
Scab subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 1	0 / 312 (0.00%) 0	0 / 315 (0.00%) 0
Scar subjects affected / exposed occurrences (all)	2 / 318 (0.63%) 2	0 / 312 (0.00%) 0	0 / 315 (0.00%) 0
Seborrhoea subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 0	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
Seborrhoeic dermatitis subjects affected / exposed occurrences (all)	3 / 318 (0.94%) 3	2 / 312 (0.64%) 2	5 / 315 (1.59%) 5
Skin depigmentation subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 1	0 / 312 (0.00%) 0	0 / 315 (0.00%) 0
Skin lesion subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
Urticaria subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 1	1 / 312 (0.32%) 4	2 / 315 (0.63%) 2
Renal and urinary disorders Pollakiuria subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Urine odour abnormal subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
Endocrine disorders			

Hypothyroidism subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Delayed fontanelle closure subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
Facial asymmetry subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Rickets subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 1	0 / 312 (0.00%) 0	0 / 315 (0.00%) 0
Torticollis subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 1	0 / 312 (0.00%) 0	0 / 315 (0.00%) 0
Infections and infestations			
Acute tonsillitis subjects affected / exposed occurrences (all)	4 / 318 (1.26%) 5	1 / 312 (0.32%) 2	6 / 315 (1.90%) 7
Bacteriuria subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 1	0 / 312 (0.00%) 0	0 / 315 (0.00%) 0
Bronchiolitis subjects affected / exposed occurrences (all)	9 / 318 (2.83%) 12	8 / 312 (2.56%) 12	13 / 315 (4.13%) 16
Bronchitis subjects affected / exposed occurrences (all)	69 / 318 (21.70%) 95	60 / 312 (19.23%) 79	48 / 315 (15.24%) 66
Candida nappy rash subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 3	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Candidiasis subjects affected / exposed occurrences (all)	2 / 318 (0.63%) 2	0 / 312 (0.00%) 0	0 / 315 (0.00%) 0
Conjunctivitis infective			

subjects affected / exposed	1 / 318 (0.31%)	4 / 312 (1.28%)	1 / 315 (0.32%)
occurrences (all)	1	5	1
Cystitis			
subjects affected / exposed	0 / 318 (0.00%)	2 / 312 (0.64%)	0 / 315 (0.00%)
occurrences (all)	0	2	0
Dacryocanaliculitis			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences (all)	0	0	1
Dermatophytosis			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences (all)	1	0	0
Ear infection			
subjects affected / exposed	10 / 318 (3.14%)	4 / 312 (1.28%)	6 / 315 (1.90%)
occurrences (all)	14	4	8
Enterobiasis			
subjects affected / exposed	2 / 318 (0.63%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	2	1	0
Enterocolitis infectious			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	1 / 315 (0.32%)
occurrences (all)	0	1	1
Erythema infectiosum			
subjects affected / exposed	0 / 318 (0.00%)	2 / 312 (0.64%)	0 / 315 (0.00%)
occurrences (all)	0	2	0
Escherichia infection			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences (all)	1	0	0
Exanthema subitum			
subjects affected / exposed	23 / 318 (7.23%)	40 / 312 (12.82%)	29 / 315 (9.21%)
occurrences (all)	32	41	29
Fungal infection			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences (all)	0	0	1
Fungal skin infection			
subjects affected / exposed	1 / 318 (0.31%)	2 / 312 (0.64%)	1 / 315 (0.32%)
occurrences (all)	1	2	1
Gastroenteritis			

subjects affected / exposed	14 / 318 (4.40%)	18 / 312 (5.77%)	12 / 315 (3.81%)
occurrences (all)	15	19	14
Gastroenteritis rotavirus			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal infection			
subjects affected / exposed	1 / 318 (0.31%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	1	1	0
Gastrointestinal viral infection			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	0	1	0
Herpangina			
subjects affected / exposed	0 / 318 (0.00%)	2 / 312 (0.64%)	1 / 315 (0.32%)
occurrences (all)	0	2	1
Herpes dermatitis			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences (all)	1	0	0
Impetigo			
subjects affected / exposed	4 / 318 (1.26%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences (all)	4	0	1
Infection			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences (all)	1	0	0
Laryngitis			
subjects affected / exposed	6 / 318 (1.89%)	11 / 312 (3.53%)	6 / 315 (1.90%)
occurrences (all)	8	11	6
Lower respiratory tract infection			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	0	1	0
Mononucleosis syndrome			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	0 / 315 (0.00%)
occurrences (all)	0	1	0
Nasopharyngitis			
subjects affected / exposed	70 / 318 (22.01%)	55 / 312 (17.63%)	62 / 315 (19.68%)
occurrences (all)	116	80	105
Oral candidiasis			

subjects affected / exposed	4 / 318 (1.26%)	6 / 312 (1.92%)	4 / 315 (1.27%)
occurrences (all)	6	6	5
Oral herpes			
subjects affected / exposed	0 / 318 (0.00%)	1 / 312 (0.32%)	1 / 315 (0.32%)
occurrences (all)	0	1	1
Otitis externa			
subjects affected / exposed	0 / 318 (0.00%)	3 / 312 (0.96%)	0 / 315 (0.00%)
occurrences (all)	0	3	0
Otitis media			
subjects affected / exposed	12 / 318 (3.77%)	13 / 312 (4.17%)	12 / 315 (3.81%)
occurrences (all)	15	15	16
Otitis media acute			
subjects affected / exposed	4 / 318 (1.26%)	1 / 312 (0.32%)	3 / 315 (0.95%)
occurrences (all)	4	1	3
Pertussis			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences (all)	1	0	0
Pharyngitis			
subjects affected / exposed	44 / 318 (13.84%)	48 / 312 (15.38%)	37 / 315 (11.75%)
occurrences (all)	49	67	46
Pharyngotonsillitis			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences (all)	0	0	1
Pneumonia			
subjects affected / exposed	7 / 318 (2.20%)	2 / 312 (0.64%)	3 / 315 (0.95%)
occurrences (all)	7	2	3
Pyelonephritis			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences (all)	1	0	0
Rash pustular			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences (all)	0	0	1
Respiratory tract infection			
subjects affected / exposed	26 / 318 (8.18%)	21 / 312 (6.73%)	30 / 315 (9.52%)
occurrences (all)	33	26	32
Respiratory tract infection viral			

subjects affected / exposed occurrences (all)	2 / 318 (0.63%) 2	5 / 312 (1.60%) 6	1 / 315 (0.32%) 2
Roseola			
subjects affected / exposed occurrences (all)	5 / 318 (1.57%) 5	2 / 312 (0.64%) 2	1 / 315 (0.32%) 1
Scarlet fever			
subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
Sialoadenitis			
subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 1	0 / 312 (0.00%) 0	0 / 315 (0.00%) 0
Skin bacterial infection			
subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 1	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Skin candida			
subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	1 / 312 (0.32%) 1	1 / 315 (0.32%) 1
Skin infection			
subjects affected / exposed occurrences (all)	2 / 318 (0.63%) 3	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
Staphylococcal skin infection			
subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 1	0 / 312 (0.00%) 0	0 / 315 (0.00%) 0
Tonsillitis			
subjects affected / exposed occurrences (all)	6 / 318 (1.89%) 8	12 / 312 (3.85%) 12	6 / 315 (1.90%) 6
Tonsillitis streptococcal			
subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
Tracheitis			
subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	4 / 312 (1.28%) 4	2 / 315 (0.63%) 2
Upper respiratory tract infection			
subjects affected / exposed occurrences (all)	87 / 318 (27.36%) 145	78 / 312 (25.00%) 126	98 / 315 (31.11%) 159
Urinary tract infection			

subjects affected / exposed occurrences (all)	11 / 318 (3.46%) 15	11 / 312 (3.53%) 13	8 / 315 (2.54%) 9
Varicella subjects affected / exposed occurrences (all)	3 / 318 (0.94%) 3	6 / 312 (1.92%) 6	8 / 315 (2.54%) 8
Viral infection subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	6 / 312 (1.92%) 6	5 / 315 (1.59%) 5
Viral rash subjects affected / exposed occurrences (all)	3 / 318 (0.94%) 3	0 / 312 (0.00%) 0	0 / 315 (0.00%) 0
Viral skin infection subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	2 / 318 (0.63%) 3	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Vulvitis subjects affected / exposed occurrences (all)	3 / 318 (0.94%) 4	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Vulvovaginal candidiasis subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 1	0 / 312 (0.00%) 0	1 / 315 (0.32%) 3
Vulvovaginitis subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 1	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Injection site pustule subjects affected / exposed occurrences (all)	0 / 318 (0.00%) 0	1 / 312 (0.32%) 1	0 / 315 (0.00%) 0
Metabolism and nutrition disorders Cow's milk intolerance subjects affected / exposed occurrences (all)	1 / 318 (0.31%) 1	0 / 312 (0.00%) 0	1 / 315 (0.32%) 1
Decreased appetite subjects affected / exposed occurrences (all)	107 / 318 (33.65%) 152	118 / 312 (37.82%) 173	113 / 315 (35.87%) 177

Dehydration			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences (all)	1	0	0
Feeding disorder neonatal			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences (all)	0	0	1
Increased appetite			
subjects affected / exposed	0 / 318 (0.00%)	2 / 312 (0.64%)	1 / 315 (0.32%)
occurrences (all)	0	2	1
Iron deficiency			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences (all)	0	0	1
Lactose intolerance			
subjects affected / exposed	1 / 318 (0.31%)	0 / 312 (0.00%)	0 / 315 (0.00%)
occurrences (all)	1	0	0
Underweight			
subjects affected / exposed	0 / 318 (0.00%)	0 / 312 (0.00%)	1 / 315 (0.32%)
occurrences (all)	0	0	1
Weight gain poor			
subjects affected / exposed	1 / 318 (0.31%)	1 / 312 (0.32%)	1 / 315 (0.32%)
occurrences (all)	1	1	1

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported